Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion

European Journal of Ophthalmology

Volumn 24, Issue 1, 2013, Pages 1-9

  Coscas, Gabriel ^a   Augustin, Albert ^b   Bandello, Francesco ^c   De Smet, Marc D ^d   Lanzetta, Paolo ^e   Staurenghi, Giovanni ^f   Parravano, Maria Cristina ^g   Udaondo, Patricia ^h   Moisseiev, Elad ⁱ   Soubrane, Gisele ^j   Yatziv, Yossi ⁱ   Loewenstein, Anat ⁱ  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^b STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d Clinique de Montchoisi   (Switzerland)

^e UNIVERSITY OF UDINE   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g IRCCS FONDAZIONE BIETTI   (Italy)

^h HOSPITAL UNIVERSITARIO LA FE   (Spain)

ⁱ TEL AVIV UNIVERSITY   (Israel)

^j HÔTEL DIEU   (France)

more..

Author keywords

Dexamethasone implant; Macular edema; Ozurdex; Retinal vein occlusion; Retreatment

Indexed keywords

DEXAMETHASONE; VASCULOTROPIN ANTIBODY;

ADULT; AGED; ARTICLE; CATARACT; CENTRAL MACULAR THICKNESS; CENTRAL RETINA VEIN OCCLUSION; CLINICAL PRACTICE; DISEASE DURATION; DRUG EFFICACY; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; RETINAL THICKNESS; RETREATMENT; RETROSPECTIVE STUDY; VERY ELDERLY; VISUAL ACUITY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DELAYED-ACTION PREPARATIONS; DEXAMETHASONE; DRUG IMPLANTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HUMANS; INJECTIONS, INTRAOCULAR; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; RETREATMENT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84889632758     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000376     Document Type: Article

References (34)

1. Coscas G, Dhermy P. Occlusions veineuses rétiniennes. Paris: Masson; 1978; 283-346.
2. Hayreh SS. Classification of central retinal vein occlusion. Ophthalmology 1983;90:458-474.
3. The Branch Vein Occlusion Study Group. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Arch Ophthalmol 1986;104:34-41.
4. The Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for isch-emic central vein occlusion. Ophthalmology 1995;102: 1434-1444.
5. Wong TY, Scott IU. Clinical practice. Retinal-vein occlusion. N Engl J Med 2010;25: 363:2135-2144.
6. Rehak J, Rehak M. Branch retinal vein occlusion: pathogen-esis, visual prognosis, and treatment modalities. Curr Eye Res 2008;33:111-131.
7. Jonas J, Paques M, Monés J, Glacet-Bernard A. Retinal vein occlusions. In: Coscas G, ed. Macular Edema. Dev Ophthal-mol 2010;47:111-135.
8. Coscas G, Loewenstein A, Augustin A, et al. Management of retinal vein occlusion: consensus document. Ophthalmo-logica 2011;226:4-28.
9. Haller J, Bandello F, Belfort R Jr, et al, Ozurdex GENEVA Study Group. Randomized, sham-controlled trial of dexametha-sone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117: 1134-1146.
10. Haller JA, Bandello F, Belfort R Jr, et al, Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118:2453-2460.
11. SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macu-lar edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study report 6. Arch Ophthalmol 2009;127: 1115-1128.
12. SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macu-lar edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study report 5. Arch Ophthalmol 2009;127: 1101-1114.
13. Kuppermann BD, Blumenkranz MS, Haller JA, et al, Dexa-methasone DDS Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Oph-thalmol 2007;125:309-317.
14. Campochiaro PA, Heier JS, Feiner L, et al.; BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1102-1112.
15. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011;118:1594-1602.
16. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011;118:2041-2049.
17. Brown DM, Campochiaro PA, Singh RP, et al, CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117: 1124-1133.
18. Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology 2012;119: 2587-2591.
19. Axer-Siegel R, Dotan A, Mimouni K, Bor E, Weinberger D, Bourla DH. Intravitreous bevacizumab treatment for macular edema due to central retinal vein occlusion. Curr Eye Res 2012;37:818-822.
20. Siegel RA, Dreznik A, Mimouni K, Bor E, Weinberger D, Bourla DH. Intravitreal bevacizumab treatment for macular edema due to branch retinal vein occlusion in a clinical setting. Curr Eye Res 2012;37:823-829.
21. Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 2013;155:429-437.
22. Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacoki-netics and pharmacodynamics of a sustained-release dexa-methasone intravitreal implant. Invest Ophthalmol Vis Sci 2011;52:80-86.
23. Holladay JT. Proper method for calculating average visual acuity. J Refract Surg 1997;13:388-391.
24. H. Schulze-Bonsel, K.N. Feltgen, Burau H, et al. Visual acuities "hand motion" and "counting fingers" can be quantified with the Freiburger visual acuity test. Invest Ophthalmol Vis Sci 2006;47:1236-1240.
25. Querques L, Querques G, Lattanzio R, et al. Repeated Intra-vitreal Dexamethasone Implant (Ozurdex®) for Retinal Vein Occlusion. Ophthalmologica 2013;229:21-25.
26. Augustin A. Poster presented at the 2012 European Association for Eye and Vision Research (EVER) Congress; October 10-13; Nice, France.
27. Pommier S. Poster presented at the 2012 EVER Congress; October 10-13; Nice, France.
28. Dodwell DG, Krimmel DA. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO); May 6-10 2012; Fort Lauderdale, Florida, USA.
29. Mayer WJ, Wolf A, Kernt M, et al. Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion. Eye Epub 2013 Apr 19.
30. Matonti F, Hoffart L, Baeteman C, Denis D. Repeated treatment for macular edema in vein occlusion by intravitreal implant of dexamethasone. Case Rep Ophthalmol 2012;3: 339-342.
31. Moisseiev E, Goldstein M, Waisbourd M, Barak A, Loewenstein A. Long term evaluation of the visual prognosis in patients treated with dexamethasone intravitreal implant (Ozurdex) for macular edema due to retinal vein occlusion. Eye 2013;27:65-71.
32. Risard SM, Pieramici DJ, Rabena MD, et al. Intravitreal ra-nibizumab for macular edema secondary to central retinal vein occlusion. Retina 2011;31:1060-1067.
33. Chang LK, Spaide RF, Klancnik JM, et al. Longer-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Retina 2011;31:821-828.
34. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 2012;119:802-809.